Product Information
ETHOSUXIMIDE 250 MG/5 ML SOLN is a generic product labeled by PAI Holdings LLC, priced at $0.1004 per ML under NDC 00121067016. Its NADAC has been published 625 times since Aug 27, 2014.
FDA first approved this application on Nov 22, 2000. Its Orange Book therapeutic-equivalence code is AA.
The Low Outlier badge above means this manufacturer's average price in the ETHOSUXIMIDE market falls below Q1 − 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/5mL
Manufacturer
PAI Holdings LLCNDC
00121067016
Classification
Generic
Dosage Form
SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ETHOSUXIMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040253FDA Approved
11/22/2000
TE Code
AA
On Market Since
11/22/2000
Pharmacological Classes
Price Statistics
The NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has been published 625 times since Aug 27, 2014, and over the history we have for it it has declined 56.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1004 per ML |
|---|---|
| All-time high | $0.3226 (Feb 11, 2015) |
| All-time low | $0.0626 (Jul 20, 2022) |
| 52-week high | $0.1004 |
| 52-week low | $0.0879 |
| Median price | $0.1929 |
| Average price | $0.1794 |
| Largest weekly change | +46.5% (Aug 22, 2018) |
| Weeks tracked | 625 |
| Tracking since | Aug 27, 2014 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the ETHOSUXIMIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ETHOSUXIMIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ETHOSUXIMIDE 250 MG/5 ML SOLN?
The current National Average Drug Acquisition Cost (NADAC) for ETHOSUXIMIDE 250 MG/5 ML SOLN, manufactured by PAI Holdings LLC, is $0.1004 per ML (NDC 00121067016), effective Sep 30, 2026.
How has the price of ETHOSUXIMIDE 250 MG/5 ML SOLN changed over time?
Over the history we have for it, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has declined 56.4%. It has been tracked across 625 weekly CMS publications since Aug 27, 2014.
What are the highest and lowest recorded NADAC prices for ETHOSUXIMIDE 250 MG/5 ML SOLN?
Since Aug 27, 2014, the NADAC for ETHOSUXIMIDE 250 MG/5 ML SOLN has ranged from a low of $0.0626 (Jul 20, 2022) to a high of $0.3226 (Feb 11, 2015), with a median of $0.1929 per ML.
Are there cheaper alternatives to ETHOSUXIMIDE 250 MG/5 ML SOLN?
No other NADAC-published product currently shares the active ingredient and strength of ETHOSUXIMIDE 250 MG/5 ML SOLN in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ETHOSUXIMIDE 250 MG/5 ML SOLN?
ETHOSUXIMIDE 250 MG/5 ML SOLN (NDC 00121067016) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.